Form 4: Lemaitre Vascular Director Acquires Dividend Rights

Lemaitre Vascular Director Martha Shadan reported the acquisition of dividend equivalent rights tied to her unvested equity awards.

Summary

• Martha Shadan, a Director of Lemaitre Vascular Inc. (LMAT), reported the acquisition of dividend equivalent rights (DERs) on September 4, 2025.
• These DERs are linked to previously granted restricted stock unit (RSU) and performance share unit (PSU) awards.
• Each dividend equivalent right is the economic equivalent of one share of Lemaitre Vascular's common stock.
• The DERs vest proportionately with their underlying RSU and PSU awards.
• The total economic equivalent of shares acquired through these DERs on this date amounts to 3.2737 shares (0.4173 + 0.4173 + 0.7138 + 0.8546 + 0.8697).
• The underlying awards were granted on December 12, 2022, December 8, 2023, and December 6, 2024.

Sentiment

Score: 7

Explanation: The filing reports a routine acquisition of dividend equivalent rights by a director, which is a standard component of equity-based compensation and generally viewed as a neutral to slightly positive event as it aligns insider interests with shareholders.

Positives

• The acquisition of dividend equivalent rights indicates an ongoing accumulation of value for the director, further aligning her interests with those of shareholders.
• The DERs are tied to existing equity awards (RSUs and PSUs), which are common long-term incentive mechanisms designed to promote executive retention and performance.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

This is a routine insider transaction report reflecting standard executive compensation practices in the medical device industry. Equity awards, such as Restricted Stock Units (RSUs) and Performance Share Units (PSUs), along with their associated dividend equivalents, are common mechanisms used to align management interests with shareholder value creation.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Performance Share Units (PSUs) with dividend equivalent rights is a standard practice in executive compensation across various industries, including medical devices.
• Companies like Medtronic (MDT) and Boston Scientific (BSX) also utilize similar equity-based incentive programs for their directors and executives to promote long-term value creation and retention, making this compensation structure consistent with industry norms.

Related Party Transactions

• The acquisition of dividend equivalent rights by Director Martha Shadan from Lemaitre Vascular Inc. constitutes a related party transaction as part of her compensation package.

Stakeholder Impact

• Shareholders: Director's interests are further aligned with shareholders through equity-based compensation, potentially fostering long-term value creation.
• Employees: No direct impact on general employees is indicated by this specific transaction.

Key Dates

Recommendation

This Form 4 filing reports a routine acquisition of dividend equivalent rights by a director as part of their compensation. It does not contain new material information that would warrant a change in investment recommendation for Lemaitre Vascular Inc. The transaction is a standard component of equity-based compensation, aligning insider interests with shareholders, and does not indicate any fundamental shift in the company's outlook or performance.

Keywords

LMAT, Lemaitre Vascular, Martha Shadan, Form 4, Insider Transaction, Director Compensation, Dividend Equivalent Rights, Equity Awards, RSU, PSU